ApprovalTrail

Approval · Notice of Compliance 28489 · 2022

OLUMIANT: Notice of Compliance 28489

Issued June 29, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
28489
Date
June 29, 2022
Company
Eli Lilly Canada IncToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Safety updates to the Product Monograph. Convert the Product Monograph to the 2020 format

Products in this notice

BrandDINStatus today
OLUMIANTNot yet assigned—

Medicinal ingredients